Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial I Judson, J Verweij, H Gelderblom, JT Hartmann, P Schöffski, JY Blay, ... The lancet oncology 15 (4), 415-423, 2014 | 987 | 2014 |
Oxaliplatin: a review in the era of molecularly targeted therapy T Alcindor, N Beauger Current oncology 18 (1), 18-25, 2011 | 492 | 2011 |
2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer D Farge, C Frere, JM Connors, C Ay, AA Khorana, A Munoz, B Brenner, ... The Lancet Oncology 20 (10), e566-e581, 2019 | 440 | 2019 |
Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial WD Tap, H Gelderblom, E Palmerini, J Desai, S Bauer, JY Blay, T Alcindor, ... The Lancet 394 (10197), 478-487, 2019 | 313 | 2019 |
Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients … GD Demetri, SP Chawla, I Ray-Coquard, A Le Cesne, AP Staddon, ... Journal of clinical oncology 31 (19), 2485-2492, 2013 | 269 | 2013 |
Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre … WD Tap, Z Papai, BA Van Tine, S Attia, KN Ganjoo, RL Jones, S Schuetze, ... The lancet oncology 18 (8), 1089-1103, 2017 | 262 | 2017 |
Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebo-controlled phase II trial N Pavlakis, KM Sjoquist, AJ Martin, E Tsobanis, S Yip, YK Kang, YJ Bang, ... Journal of Clinical Oncology 34 (23), 2728, 2016 | 227 | 2016 |
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised … CS Fuchs, K Shitara, M Di Bartolomeo, S Lonardi, SE Al-Batran, ... The Lancet Oncology 20 (3), 420-435, 2019 | 224 | 2019 |
PICASSO III: a phase III, placebo-controlled study of doxorubicin with or without palifosfamide in patients with metastatic soft tissue sarcoma CW Ryan, O Merimsky, M Agulnik, JY Blay, SM Schuetze, BA Van Tine, ... Journal of Clinical Oncology 34 (32), 3898-3905, 2016 | 177 | 2016 |
Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations B Melosky, R Burkes, D Rayson, T Alcindor, N Shear, M Lacouture Current oncology 16 (1), 16-26, 2009 | 171 | 2009 |
2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19 D Farge, C Frere, JM Connors, AA Khorana, A Kakkar, C Ay, A Muñoz, ... The Lancet Oncology 23 (7), e334-e347, 2022 | 160 | 2022 |
Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): A single-arm, phase 1b–2 trial DVT Catenacci, YK Kang, H Park, HE Uronis, KW Lee, MCH Ng, ... The lancet oncology 21 (8), 1066-1076, 2020 | 158 | 2020 |
Activity of eribulin in patients with advanced liposarcoma demonstrated in a subgroup analysis from a randomized phase III study of eribulin versus dacarbazine GD Demetri, P Schöffski, G Grignani, JY Blay, RG Maki, BA Van Tine, ... Journal of Clinical Oncology 35 (30), 3433-3439, 2017 | 143 | 2017 |
European Organisation and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of … I Judson, J Verweij, H Gelderblom, JT Hartmann, P Schöffski, JY Blay, ... Lancet Oncol 15 (4), 415-423, 2014 | 140 | 2014 |
Immunomodulatory effects of extracorporeal photochemotherapy in patients with extensive chronic graft-versus-host disease T Alcindor, G Gorgun, KB Miller, TF Roberts, K Sprague, DP Schenkein, ... Blood, The Journal of the American Society of Hematology 98 (5), 1622-1625, 2001 | 130 | 2001 |
Perioperative docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophageal and gastric adenocarcinoma: a multicenter phase II trial LE Ferri, S Ades, T Alcindor, M Chasen, V Marcus, M Hickeson, G Artho, ... Annals of oncology 23 (6), 1512-1517, 2012 | 121 | 2012 |
Sideroblastic anaemias T Alcindor, KR Bridges British journal of haematology 116 (4), 733-743, 2002 | 102 | 2002 |
Nirogacestat, a γ-secretase inhibitor for desmoid tumors M Gounder, R Ratan, T Alcindor, P Schöffski, WT Van Der Graaf, BA Wilky, ... New England Journal of Medicine 388 (10), 898-912, 2023 | 66 | 2023 |
EGFR and K-ras gene mutation status in squamous cell anal carcinoma: a role for concurrent radiation and EGFR inhibitors? A Paliga, R Onerheim, A Gologan, G Chong, A Spatz, T Niazi, A Garant, ... British journal of cancer 107 (11), 1864-1868, 2012 | 61 | 2012 |
A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a … HJ Mackay, HJ Au, E McWhirter, T Alcindor, A Jarvi, K MacAlpine, L Wang, ... Investigational new drugs 30, 1158-1163, 2012 | 55 | 2012 |